This New LDL Study Will Change Medicine

Mike Mutzel emphasizes walking as the most fundamental, accessible daily practice for metabolic health. He positions it as one of the pillars — along with sleep, stress management, and diet — that keep the metabolic milieu from turning LDL into a dangerous particle. He doesn’t get into detailed biological pathways, but the implication is that everyday movement keeps insulin sensitivity high and inflammation low, which is critical for the Lean Mass Hyper‑Responder population to stay plaque‑free.

Mike lists this sleep hygiene practice alongside walking and stress reduction as a core tactic for metabolic health. He doesn’t provide a long justification, but the context is that poor sleep quality and irregular schedules are common in modern life and are known promoters of insulin resistance and hypertension. By stabilizing sleep, one helps maintain the optimal metabolic environment where high LDL is less likely to cause plaque.

Mike groups grounding and breathwork with other lifestyle tactics as part of metabolic optimization. While he doesn’t expand on the mechanism, he draws a direct line: stress reduction lowers oxidative stress and high‑sympathetic‑drive states that otherwise make LDL particles more prone to oxidation and artery wall deposition. This is one of the many non‑pharmacological ways people can create a protective context even with high LDL.

Mike is adamant that avoiding processed carbohydrates is central to metabolic health. He explains that these foods lead to glucose and insulin spikes, which in turn increase triglycerides — a signature of the metabolic derangement that drives atherogenesis. For the LMHR phenotype, characterized by low triglycerides and high HDL, this dietary foundation is what maintains the safe metabolic context. He contrasts that with the standard American diet, which produces a highly insulin‑resistant, inflammatory state where LDL becomes truly dangerous.

Mike frames the diet as the nutritional cornerstone of metabolic health. He specifically recommends an omnivorous style — not exclusively carnivore — and mentions prioritizing protein. He promotes his sponsor, Maui Nui Venison, as an example of nutrient‑dense, wild‑harvested red meat that fits this pattern. The deeper argument is that for LMHR, the diet produces high LDL but also high HDL and very low triglycerides, and that this triad, when coupled with leanness and insulin sensitivity, is not atherogenic. The dietary pattern thus directly sustains the very metabolic context that the study found rendered high LDL harmless.

Mike sees morning BP measurement as a low‑cost, high‑yield practice for people worried about high LDL. He recommends the free Connect app (no financial affiliation) to log and trend readings. The reasoning is that many people with elevated LDL are told they are at high CVD risk, but if their blood pressure is optimal and they show no signs of insulin resistance, the risk is likely much lower. Catching early morning hypertension — often missed in clinic — allows intervention and removes a key pro‑atherogenic stimulus from the arterial wall.

The study, titled “Plaque begets plaque, APOB does not: longitudinal data from the keto CTA trial,” enrolled 100 people who fit the LMHR phenotype: LDL >190 mg/dL, HDL >80 mg/dL, triglycerides <70 mg/dL, and a low BMI (median 22.5). Over one year, the degree of coronary artery plaque change — measured by coronary CT angiogram — showed no significant association with LDL or APOB levels. In fact, the only independent predictor of plaque progression was the baseline plaque burden itself. This means that an individual’s starting plaque load, not the amount of circulating APOB‑containing lipoproteins, drove further accumulation. The mean LDL was extremely high (254 mg/dL) and APOB was 185 mg/dL, levels that would trigger statin therapy in almost any standard protocol. Yet over the year, plaque did not worsen in lockstep with these numbers. Mike Mutzel emphasizes that this should prompt mainstream doctors to move from a “high LDL equals treat” reflex to a more nuanced assessment of metabolic health. He notes that the Miami Heart cohort data had already hinted that matched LMHR individuals with high LDL did not have more plaque than those with low LDL, and now this prospective arm confirms it.

Mike Mutzel explains that the data suggest a “plaque begets plaque” phenomenon. The presence of atherosclerotic plaque may create a local environment (possibly through inflammation, disturbed flow, or altered endothelial function) that promotes more plaque formation irrespective of circulating LDL levels. He points to the Miami Heart cohort analysis, which similarly found that baseline coronary artery calcium was the primary driver of change over time, not the apo B level. This means someone with a zero or very low calcium score and high LDL might have a very different risk trajectory than someone with a high calcium score and even moderate LDL. It also underscores the importance of preventive imaging in personalized risk assessment, rather than treating a lab number in isolation. Mike mentions that this finding forces us to ask: why did the plaque get there in the first place? He posits that drivers might have been earlier-life insulin resistance, sleep-disordered breathing, hypertension, or oxidative stress — and that the ongoing metabolic environment determines whether existing plaque becomes problematic, rather than solely the LDL count.

Mike flags that six of the 100 participants experienced a net reduction in total plaque volume over the 12 months. None were on lipid-lowering medication; they were simply following a low-carb or ketogenic diet and maintaining a lean, metabolically healthy phenotype. While the absolute change is modest, it raises the possibility that metabolic milieu (low insulin, normal blood pressure, low oxidative stress) may be a more potent determinant of plaque dynamics than LDL concentration. He speculates that the environment in which the LDL particle lives — free of high glucose, high insulin, and excess oxidative stress — could render LDL less susceptible to modification and deposition, and may even allow the artery wall to repair itself. He doesn't claim this proves causality, but he finds it hugely interesting and hopes it stimulates further research. The regression cases give hope to the many LMHR individuals who have been told by their doctors that they are on a rapid path to a heart attack.

Mike explains that LDL is essential for life — it transports coenzyme Q10, vitamin K, fat‑soluble vitamins, and cholesterol for hormone and cell membrane synthesis. The problem arises in a pro‑inflammatory, pro‑oxidant metabolic state. He notes that factors associated with insulin resistance (elevated glucose, hyperinsulinemia, high triglycerides) and hypertension can render LDL particles more susceptible to glycation and oxidation, which is what makes them deposit in the arterial wall. Sleep‑disordered breathing, which spikes sympathetic tone and oxidative stress, can also prime LDL particles for atherogenicity. He highlights that one should measure morning blood pressure, watch for snoring/apnea, and assess insulin sensitivity markers (fasting insulin, HOMA‑IR) instead of fixating solely on LDL. This view aligns with the “lipid quality over quantity” perspective: a lean, normotensive, insulin‑sensitive person with LDL 250 is in a vastly different risk category than an insulin‑resistant, hypertensive individual with LDL 150. Mike believes this is a profound insight that will take time for mainstream doctors to accept due to reimbursement pressures, appointment time limits, and reliance on simple algorithmic protocols.